studies

la/mBC - HR-positive - 1st line (L1), trastuzumab plus endocrine therapy vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsSYSUCC-002, 2022 0.82 [0.65; 1.04] 0.82[0.65; 1.04]SYSUCC-002, 202210%392NAnot evaluable progression or deaths (PFS)detailed resultsSYSUCC-002, 2022 0.88 [0.71; 1.09] 0.88[0.71; 1.09]SYSUCC-002, 202210%392NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-10 01:38 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 352,354 - treatments: 1429

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons